← Back

Wire · opportunities

Dronabinol for PTSD Nightmares Is Promising, and the Dual Diagnosis Question Changes ...

Published

24 August 2026

Topic

opportunities

◆ Sectors

Mental Health

◆ Geography

United States

◆ Source

Read at clinicaltrialvanguard.com →

◆ Verified

Fusion42 · 24 August 2026 · Fusion42 review

A recent randomized trial showed dronabinol, a synthetic THC, significantly reduced PTSD nightmares, suggesting a new treatment avenue beyond prazosin. However, the study did not address patients with comorbid substance use disorders (SUD), a large portion of the PTSD population, creating clinical and regulatory challenges for broad adoption.

This Wire brief sits within Fusion42's coverage of Mental Health.

◆ ◆ The Wire takeaway

Prescribing dronabinol for PTSD nightmares confronts you with a major clinical blind spot: comorbid substance use disorder patients are excluded from trials but form half your patient base. Address this gap immediately or risk losing market access as guidelines and real-world needs diverge.

◆ Coverage

1 source · 24 Aug 2026

◆ Related on Wire

◆ Topics

Mental Healthptsddronabinolsynthetic-thcsubstance-use-disordermental-health-treatmentoff-label-use